Mechanisms of Osteoblastic Metastases: Role of Endothelin-1

Clinical Orthopaedics and Related Research

Volumn 415, Issue SUPPL., 2003, Pages

  Mohammad, Khalid S ^b   Guise, Theresa A ^a  

^a UNIVERSITY OF VIRGINIA   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ATRASENTAN; ENDOTHELIN 1; ENDOTHELIN A RECEPTOR ANTAGONIST; ENDOTHELIN B RECEPTOR ANTAGONIST;

ANIMAL CELL; ANIMAL TISSUE; BONE METASTASIS; BREAST CANCER; CALVARIA; CANCER CELL CULTURE; CELL GROWTH; CELL PROLIFERATION; CELL STRAIN MDA MB 231; CELL STRAIN ZR 75 1; CONFERENCE PAPER; CULTURE MEDIUM; EXPERIMENTAL NEOPLASM; FEMALE; MOUSE; NONHUMAN; NUDE MOUSE; OSSIFICATION; OSTEOBLAST; PRIORITY JOURNAL; RECEPTOR BLOCKING; SOLID TUMOR;

EID: 0142157085     PISSN: 0009921X     EISSN: 15281132     Source Type: Journal    
DOI: 10.1097/01.blo.0000093047.96273.4e     Document Type: Conference Paper

References (67)

1. Alam AS, Gallagher A, Shankar V, et al: Endothelin inhibits osteoclastic bone resorption by a direct effect on cell motility: Implications for the vascular control of bone resorption. Endocrinology 130:3617-3624, 1992.
2. Asham E, Shankar A, Loizidou M, et al: Increased endothelin-1 in colorectal cancer and reduction of tumour growth by ET(A) receptor antagonism. Br J Cancer 85:1759-1763, 2001.
3. Blomme EA, Dougherty KM, Pienta KJ, et al: Skeletal metastases of prostate adenocarcinoma inrats: Morphometric analysis and role of parathyroid hormone-related protein. Prostate 39:187-197, 1999.
4. Boyce BF, Hughes DE, Wright KR, Xing L, Dai A: Recent advances in bone biology provide insight into the pathogenesis of bone diseases. Lab Invest 79:83-94, 1999.
5. Carducci MA, Nelson JB, Bowling MK, et al: Atrasentan, an endothelin-receptor antagonist for refractory adenocarcinomas: Safety and pharmacokinetics. J Clin Oncol 20:2171-2180, 2002.
6. Case Records of the Massachusetts General Hospital (case 29-1972). N Engl J Med 287:138-143, 1972.
7. Charhon SA, Chapuy MC, Delvin EE, et al: Histomorphometric analysis of sclerotic bone metastases from prostatic carcinoma: Special reference to osteomalacia. Cancer 51:918-924, 1983.
8. Chiao JW, Moonga BS, Yang YM, et al: Endothelin-1 from prostate cancer cells is enhanced by bone contact which blocks osteoclastic bone resorption. Br J Cancer 83:360-365, 2000.
9. Clarke NW, McClure J, George NJ: Osteoblast function and osteomalacia in metastatic prostate cancer. Eur Urol 24:286-290, 1993.
10. Clouthier DE, Williams SC, Yanagisawa H, et al: Signaling pathways crucial for craniofacial development revealed by endothelin-A receptor-deficient mice. Dev Biol 217:10-24, 2000.
11. Cohen P, Graves HC, Peehl DM, et al: Prostate specific antigen (PSA) is an insulin-like growth factor binding protein-3 (IGFBP-3) protease found in seminal plasma. J Clin Endocrinol Metab 75:1046-1053, 1992.
12. Cohen P, Peehl DM, Stamey TA, et al: Elevated levels of insulin-like growth factor-binding protein-2 in the serum of prostate cancer patients. J Clin Endocrinol Metab 76:1031-1035, 1993.
13. Conover CA, Perry JE, Tindall DJ: Endogenous cathepsin D-mediated hydrolysis of insulin-like growth factor-binding proteins in cultured human prostatic carcinoma cells. J Clin Endocrinol Metab 80:987-993, 1995.
14. Del Bufalo D, Di Castro V, Biroccio A, et al: Endothelin-1 protects ovarian carcinoma cells against paclitaxel-induced apoptosis: Requirement for Akt activation. Mol Pharmacol 61:524-532, 2002.
15. Gamis AS, Egelhoff J, Roloson G, et al: Diffuse bony metastases at presentation in a child with glioblastoma multiforme: A case report. Cancer 66: 180-184, 1990.
16. George J, Lai FM: Metastatic cervical carcinoma presenting as psoas abscess and osteoblastic and lytic bony metastases. Singapore Med J 36:224-227, 1995.
17. Giordano N, Nardi P, Vigni P, et al: Osteoblastic metastases from carcinoid tumor. Clin Exp Rheumatol 12:228-229, 1994. Letter,
18. Guise TA, Mundy GR: Cancer and bone. Endocr Rev 19:18-55, 1998.
19. Guise TA, Yin JJ, Taylor SD, et al: Evidence for a causal role of parathyroid hormone-related protein in breast cancer mediated-osteolysis. J Clin Inves 98: 1544-1549, 1996.
20. Jae H-S, Winn M, Dixon DB, et al: Pyrrolidine-3-carboxylic acids as endothelin antagonists: 2: Sulfonamide-based ETA/ETB mixed antagonists. J Med Chem 40:3217-3227, 1997.
21. Kanety H, Madjar Y, Dagan Y, et al: Serum insulin-like growth factor-binding protein-2 (IGFBP-2) is increased and IGFBP-3 is decreased in patients with prostate cancer: Correlation with serum prostate-specific antigen. J Clin Endocrinol Metab 77:229-233, 1993.
22. Kimmel CB, Miller CT, Moens CB: Specification and morphogenesis of the zebrafish larval head skeleton. Dev Biol 233:239-257, 2001.
23. Kingston JE, Plowman PN, Smith BF, Garvan NJ: Differentiated astrocytoma with osteoblastic skeletal metastases in a child. Childs Nervous System 2: 219-221, 1986.
24. Kinoshita A, Tamura T, Aoki C, et al: Demonstration of endothelin (ET) receptors on cultured rabbit chondrocytes and stimulation of DNA synthesis and calcium influx by ET-1 via its receptors. Cell Biol Int 19:647-654, 1995.
25. Kitano Y, Kurihara H, Kurihara Y, et al: Gene expression of bone matrix proteins and endothelin receptors in endothelin-1-deficient mice revealed by in situ hybridization. J Bone Miner Res 13:237-244, 1998.
26. Kitten AM, Andrews CJ: Endothelin-1 expression in long-term culture of fetal rat calvarial osteoblasts: Regulation by BMP-7. J Cell Physiol 187:218-225, 2001.
27. Kitten AM, Harvey SA, Criscimagna N, et al: Osteogenic protein-1 downregulates endothelin A receptors in primary rat osteoblasts. Am J Physiol 272: E967-975, 1997.
28. Koutsilieris M: Skeletal metastases in advanced prostate cancer: Cell biology and therapy. Crit Rev Oncol Hematol 18:51-64, 1995.
29. Koutsilieris M, Frenette G, Lazure C, et al: Urokinase-type plasminogen activator: A paracrine factor regulating the bioavailability of IGFs in PA-III cell-induced osteoblastic metastases. Anticancer Res 13:481-486, 1993.
30. Koutsilieris M, Polychronakos C: Proteinolytic activity against IGF-binding proteins involved in the paracrine interactions between prostate adenocarcinoma cells and osteoblasts. Anticancer Res 12:905-910, 1992.
31. Kurihara Y, Kurihara H, Suzuki H, et al: Elevated blood pressure and craniofacial abnormalities in mice deficient in endothelin-1. Nature 368:703-710, 1994.
32. Le Brun G, Aubin P, Soliman H, et al: Upregulation of endothelin I and its precursor by IL-1beta, TNF-alpha, and TGF-beta in the PC3 human prostate cancer cell line. Cytokine 11:157-162, 1999.
33. Lee Y, Schwarz E, Davies M, et al: Differences in the cytokine profiles associated with prostate cancer cell induced osteoblastic and osteolytic lesions in bone. J Orthop Res 21:62-72, 2003,
34. Levin ER: Endothelins. N Engl J Med 333:356-365, 1995.
35. Liaw CC, Ho YS, Koon-Kwan NG, Chen TL, Tzann WC: Nasopharyngeal carcinoma with brain metastasis: A case report. J Neurooncol 22:227-230, 1994.
36. Lodhi KM, Sakaguchi H, Hirose S, Shibabe S, Hagiwara H: Perichondrial localization of ETA receptor in rat tracheal and xiphoid cartilage and in fetal rat epiphysis. Am J Physiol 268:C496-502, 1995.
37. Masukawa H, Miura Y, Sato I, Oiso Y, Suzuki A: Stimulatory effect of endothelin-1 on Na-dependent phosphate transport and its signaling mechanism in osteoblast-like cells. J Cell Biochem 83:47-55, 2001.
38. McLennan MK: Case report 657: Malignant epithelial thymoma with osteoblastic metastases. Skeletal Radiol 20:141-144, 1991.
39. Mundy G, Garrett R, Harris S, et al: Stimulation of bone formation in vitro and in rodents by statins. Science 286:1946-1949, 1999.
40. Nelson JB, Hedican SP, George DJ, et al: Identification of endothelin-1 in the pathophysiology of metastatic adenocarcinoma of the prostate. Nat Med 1:944-949, 1995.
41. Nelson JB, Lee WH, Nguyen SH, et al: Endothelin-1 production and decreased endothelin B receptor expression in advanced prostate cancer. Cancer Res 56:663-668, 1996.
42. A receptor blockade. Urology 53:2063-2069, 1999.
43. Opgenorth TJ, Adler AL, Calzadilla SV, et al: Pharmacological characterization of A-127722: An orally active and highly potent ETA-selective receptor antagonist. J Pharmacol Exp Ther 276:473-481, 1996.
44. Paget S: The distribution of secondary growths in cancer of the breast. Lancet 1:571-572, 1889.
45. Paling MR, Pope TL: Computed tomography of isolated osteoblastic colon metastases in the bony pelvis. J Comput Tomogr 12:203-207, 1988.
46. Parfitt AM: The mechanism of coupling: A role for the vasculature. Bone 26:319-323, 2000.
47. Patel KV, Schrey MP: Human breast cancer cells contain a phosphoramidon-sensitive metalloproteinase which can process exogenous big endothelin-1 to endothelin-1: A proposed mitogen for human breast fibroblasts. Br J Cancer 71:442-447, 1995.
48. Pederson RT, Haidak DJ, Ferris RA, Macdonald JS, Schein PS: Osteoblastic bone metastasis in Zollinger-Ellison syndrome. Radiology 118:63-64, 1976.
49. Pingi A, Trasimeni G, Di Biasi C, et al: Diffuse leptomeningeal gliomatosis with osteoblastic metastases and no evidence of intraaxial lesions. Am J Neuroradiol 16:1018-1020, 1995.
50. Rosano L, Varmi M, Salani D, et al: Endothelin-1 induces tumor proteinase activation and invasiveness of ovarian carcinoma cells. Cancer Res 61:8340-8346, 2001.
51. Rosol TJ: Pathogenesis of bone metastases: Role of tumor-related proteins. J Bone Miner Res 15:844-850, 2000.
52. Sasaki T, Hong MH: Endothelin-1 localization in bone cells and vascular endothelial cells in rat bone marrow. Anat Rec 237:332-337, 1993.
53. Sasaki T, Hong MH: Localization of endothelin-1 in the osteoclast. J Electron Microsc 42:193-196, 1993.
54. Scher HI, Chung LWK: Bone metastases: Improving the theraputic index. Semin Oncol 21:630-656, 1994.
55. Shioide M, Noda M: Endothelin modulates osteopontin and osteocalcin messenger ribonucleic acid expression in rat osteoblastic osteosarcoma cells. J Cell Biochem 53:176-180, 1993.
56. Stephenson J: Experimental prostate cancer drugs slow disease progression. JAMA 286:34, 2001.
57. Stem PH, Tatrai A, Semler DE, et al: Endothelin receptors, second messengers, and actions in bone. J Nutr 125(Suppl):2028S-2032S, 1995.
58. Takuwa Y, Masaki T, Yamashita K: The effects of the endothelin family peptides on cultured osteoblastic cells from rat calvariae. Biochem Biophys Res Commun 170:998-1005, 1990.
59. Tatrai A, Foster S, Lakatos P, Shankar G, Stem PH: Endothelin-1 actions on resorption, collagen and noncollagen protein synthesis,and phosphatidylinositol turnover in bone organ cultures. Endocrinology 131:603-607, 1992.
60. Tennant MK, Thrasher JB, Twomey PA, Birnbaum RS, Plymate SR: Insulin-like growth factor-binding protein-2 and -3 expression in benign human prostate epithelium, prostate intraepithelial neoplasia, and adenocarcinoma of the prostate. J Clin Endocrinol Metab 81:411-420, 1996.
61. Von Geldem TW, Tasker AS, Sorensen BK, et al: Pyrrolidine-3-carboxylic acids as endothelin antagonists: 4: Side chain conformational restriction leads to ETB selectivity. J Med Chem 42:3668-3678, 1999.
62. Yanagisawa M, Kurihara H, Kimura S, et al: A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 332:411-415, 1988.
63. Yang J, Fizazi K, Peleg S, et al: Prostate cancer cells induce osteoblast differentiation through a Cbfal-dependent pathway. Cancer Res 61:5652-5659, 2001.
64. Yi B, Williams PJ, Niewolna M, Wang Y, Yoneda T: Tumor-derived platelet-derived growth factor-BB plays a critical role in osteosclerotic bone metastasis in an animal model of human breast cancer. Cancer Res 62:917-923, 2002.
65. Yin JJ, Selander KS, Chirgwin JM, et al: TGF-β signaling blockade inhibits parathyroid hormone-related protein secretion by breast cancer cells and bone metastases development. J Clin Invest 103:197-206, 1999.
66. Yorimitsu K, Moroi K, Inagaki N, et al: Cloning and sequencing of a human endothelin converting enzyme in renal adenocarcinoma (ACHN) cells producing endothelin-2. Biochem Biophy Res Commun 208: 721-727, 1995.
67. Zhang J, Dai J, Lin DL, et al: Osteoprotegerin inhibits prostate cancer-induced osteoclastogenesis and prevents prostste tumor growth in the bone. J Clin Invest 107:1235-1244, 2001.